🇺🇸 FDA
Pipeline program

PD-L1, PD-L2 peptides with Montanide ISA51

CLL19H1

Phase 2 other completed

Quick answer

PD-L1, PD-L2 peptides with Montanide ISA51 for Chronic Lymphocytic Leukemia is a Phase 2 program (other) at IO Biotech with 1 ClinicalTrials.gov record(s).

Program details

Company
IO Biotech
Indication
Chronic Lymphocytic Leukemia
Phase
Phase 2
Modality
other
Status
completed

Clinical trials